CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+6.25%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$17.4B
AUM Growth
+$904M
(+5.5%)
Cap. Flow
+$91.5M
Cap. Flow
% of AUM
0.53%
Top 10 Holdings %
Top 10 Hldgs %
29.78%
Holding
731
New
36
Increased
329
Reduced
218
Closed
40
Top Buys
| 1 |
Amgen
AMGN
|
$65.4M |
| 2 |
Amazon
AMZN
|
$57.7M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$54.5M |
| 4 |
BioNTech
BNTX
|
$41.3M |
| 5 |
Advanced Micro Devices
AMD
|
$40.5M |
Top Sells
| 1 |
Lam Research
LRCX
|
$122M |
| 2 |
Thermo Fisher Scientific
TMO
|
$63.5M |
| 3 |
Applied Materials
AMAT
|
$43.1M |
| 4 |
Nu Holdings
NU
|
$36.4M |
| 5 |
Incyte
INCY
|
$33.7M |
Sector Composition
| 1 | Technology | 31.8% |
| 2 | Healthcare | 28.54% |
| 3 | Financials | 9.44% |
| 4 | Consumer Discretionary | 7.84% |
| 5 | Industrials | 7.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
626
CGI
GIB
$21.4B
| $258K | ﹤0.01% |
+2,241
| New | +$258K |
|
627
BCE
BCE
$23.1B
| $252K | ﹤0.01% |
7,236
| – | – |
|
628
American Eagle Outfitters
AEO
$3.13B
| $249K | ﹤0.01% |
11,142
-858
| -7% | -$19.2K |
|
629
ASE Group
ASX
$22.7B
| $218K | ﹤0.01% |
22,315
+2,195
| +11% | +$21.4K |
|
630
Nutanix
NTNX
$18.7B
| $217K | ﹤0.01% |
+3,655
| New | +$217K |
|
631
Lennox International
LII
$20.1B
| $210K | ﹤0.01% |
+348
| New | +$210K |
|
632
Graco
GGG
$14.2B
| $208K | ﹤0.01% |
+2,382
| New | +$208K |
|
633
Republic Services
RSG
$71.6B
| $207K | ﹤0.01% |
1,032
| – | – |
|
634
Gold Fields
GFI
$30.9B
| $195K | ﹤0.01% |
12,675
| – | – |
|
635
United Microelectronic
UMC
$17.1B
| $192K | ﹤0.01% |
22,764
+2,239
| +11% | +$18.9K |
|
636
CommScope
COMM
$3.59B
| $171K | ﹤0.01% |
+28,054
| New | +$171K |
|
637
Lumen
LUMN
$4.87B
| $166K | ﹤0.01% |
+23,408
| New | +$166K |
|
638
Nektar Therapeutics
NKTR
$720M
| $103K | ﹤0.01% |
5,306
| – | – |
|
639
CEMIG Preferred Shares
CIG
$5.89B
| $68.6K | ﹤0.01% |
33,294
| – | – |
|
640
Ally Financial
ALLY
$12.8B
| – | – |
0
| – | -$12.8M |
|
641
Ares Management
ARES
$38.8B
| – | – |
-68,781
| Closed | -$9.17M |
|
642
Arrowhead Research
ARWR
$4.02B
| – | – |
-228,054
| Closed | -$5.93M |
|
643
Brink's
BCO
$4.73B
| – | – |
-20,920
| Closed | -$2.14M |
|
644
Brookfield Renewable
BEPC
$5.94B
| – | – |
-11,551
| Closed | -$327K |
|
645
Blackrock
BLK
$170B
| – | – |
-11,870
| Closed | -$9.35M |
|
|
BPMC
646
DELISTED
Blueprint Medicines
BPMC
| – | – |
-52,066
| Closed | -$5.61M |
|
647
Celldex Therapeutics
CLDX
$1.54B
| – | – |
-317,509
| Closed | -$11.8M |
|
648
Caribou Biosciences
CRBU
$173M
| – | – |
-625,063
| Closed | -$1.03M |
|
649
Crocs
CROX
$4.79B
| – | – |
-17,584
| Closed | -$2.57M |
|
650
CytomX Therapeutics
CTMX
$350M
| – | – |
-210,027
| Closed | -$256K |
|